Methylphenidate prodrug - KemPharm

Drug Profile

Methylphenidate prodrug - KemPharm

Alternative Names: D-threo-methylphenidate prodrug - KemPharm; KP 415; KP 484; KP415 Prodrug; Methylphenidate-prodrug-KemPharm

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator KemPharm
  • Class Behavioural disorder therapies; Phenylacetates; Piperidines; Small molecules
  • Mechanism of Action Adrenergic receptor modulators; Central nervous system stimulants; Dopamine release stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Attention-deficit hyperactivity disorder

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder

Most Recent Events

  • 09 Jul 2018 Efficacy and adverse events data from a phase III trial in Attention-deficit/hyperactivity disorder released by KemPharm
  • 18 May 2018 KemPharm completes a phase III trial in Attention-deficit hyperactivity disorder (In children) in USA (PO) (NCT03292952)
  • 10 May 2018 Positive top-line efficacy and pharmacokinetics data from the KP415.A03 trial in Attention-deficit hyperactivity disorder released by KemPharm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top